Biotech & MedTech News
-
Voyageur Secures $687k of Additional Capital from Warrant Exercises
Voyageur streamlines capitalization table through exercise of 5,725,829 warrants, expiry of 8,844,935 warrants Strong existing shareholder support, raising…
-
Voyageur Recaps Significant 2024 Achievements and Unveils Plans for Transformational 2025, Including Market Launch for Barium Suite of Products and Advancement of Iodine Suite
LOI with Multinational Contrast Media Company Voyageur Introduced Five New Health Canada Licensed Barium Contrast Products Securing 1st…
-
DIAGNOS Announces the Engagement of Promoter
January 13, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
Alyea Therapeutics to Present at Biotech Showcase 2025 During 43rd Annual J.P. Morgan Healthcare Conference Week
Finalist to present at RESI JPM IPC and attend the Nasdaq Opening Bell Ceremony on January 13 January…
-
Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform
Coeptis Secures Five New Clients With Total Contract Value of $1.7 Million Dollars With More On The Horizon Signaling AI-Driven…
-
Coeptis Therapeutics Announces Reverse Stock Split
December 27, 2024 (Source) — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company focused…
-
Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies
Coeptis Aims to Bring AI Innovation in Biotechnology and Technology December 26, 2024 (Source) — Coeptis Therapeutics Holdings,…
-
Voyageur Pharmaceuticals Ltd. Signs Letter of Intent with Global Contrast Imaging Company to Expand Market Reach and Product Portfolio
LOI Agreement is steppingstone to formal agreement, The Multinational Pharmaceutical company is ranked in the top five contrast…
-
Voyageur Announces Closing of Final Tranche of Private Placement
December 18, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Corporation”), is pleased…
-
Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies
Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a Risk Mitigation Software Company with 10,000 customers…
